sEV enrichment was verified by transmission electron microscopy and western blotting using antibodies against ALIX, TSG101, CD63, CD81, CD9 (sEV markers), and also against GRP94 (negative control), HSP70 (cancer biomarker) [18], and PD-L1 (Fig. 3c–e). The gene discussed is CD81; the disease is cancer.